许玲辉, 顾雅佳. Application and evaluation of magnetic resonance imaging in the multidisciplinary treatment of breast cancer[J]. China Oncology, 2013, 23(8): 613-617.
许玲辉, 顾雅佳. Application and evaluation of magnetic resonance imaging in the multidisciplinary treatment of breast cancer[J]. China Oncology, 2013, 23(8): 613-617. DOI: 10.3969/j.issn.1007-3969.2013.08.009.
Application and evaluation of magnetic resonance imaging in the multidisciplinary treatment of breast cancer
It has been shown that MR imaging of breast is superior to conventional mammography and ultrasonography on early diagnosis and cancer staging on breast cancer due to MRI’s high soft-tissue contrast and no radiation. The concept of multidisciplinary treatment of breast cancer has been increasingly accepted in clinical practice of breast cancer care. Investigation of breast MRI on cancer staging
selecting conservative therapy
detecting the primary malignant of patients presenting as axillary metastases
evaluating residual disease after neoadjuvant chemotherapy(NAC)
predicting response in the early phase of treatment as well as monitoring recurrence during follow-up has been carried out along with its board clinical application. The advantages of breast MRI in mapping the disease accurately provide measures to select appropriate use of variable treatments.
Research progress and prospects of MRI in predicting lymph node status in breast cancer
Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)
Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives
A study of 30-year trends in incidence and mortality risks of breast cancer among young women in China
Impact of miR-193a-3p on migration and invasion of breast cancer stem cells through targeting TRIM14
Related Author
Zihan ZHAI
Sheng CHEN
The Society of Breast Cancer China Anti-Cancer Association
Breast Oncology Group of the Oncology Branch of the Chinese Medical Association
LU Ye
ZHANG Wenxiang
KONG Xiangyi
FANG Yi
Related Institution
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
Shanghai Engineering Research Center of Artificial Intelligence Technology for Tumor Diseases